nternational Circulation: Would you like to introduce the advance in research on oral anticoagulants? Do you think using oral the factor Xa inhibitor rivaroxaban is safe enough for the patients with deep vein thrombosis， though we know some trials (ROCKET， ATLAS) have showed its efficacy and safety for other diseases?

《国际循环》：口服抗凝药物的研究方面有何新进展？虽然已有研究如ROCKET， ATLAS等证实了口服抗Xa因子抑制剂在一些疾病中的有效性和安全性，但在深静脉血栓治疗方面使用的安全性如何？

Prof. Cohen: We will know soon the answer to that question as we are doing the "EINSTEIN" studies in the treatment of DVT and PE. it seems to be very safe in DVT and PE prevention (RECORD studies).

Cohen教授：只要进行EINSTEIN研究，我们会很快知道利伐沙班治疗深静脉血栓形成和肺栓塞效果的答案， RECORD研究中利伐沙班在预防深静脉血栓形成和肺栓塞似乎是非常安全的

International Circulation: As for patients who have high risk of venous thromboembolism .How can we prevent DVT？

《国际循环》：您认为血栓栓塞性事件高危患者应如何预防深静脉血栓形成？

Prof. Cohen: I will be recommending rivaroxaban once it is licensed and this can be combined with early mobilisation and mechanical methods such as stockings.

Cohen教授：只要利伐沙班得到批准，我会推荐应用，它可早期服用，并可与机械法如弹力袜合用。

International Circulation: During the long term anticoagulants therapy of pulmonary embolism， there is no certain indication of stopping treatment. How to master the indication of stopping treatment of anticoagulants?

《国际循环》：肺栓塞患者在初期抗凝治疗后进入长期抗凝治疗过程中时，目前尚无非常明确停用抗凝药物的指征，请问您是如何掌握这一指征的？有无好的经验介绍？

Prof. Cohen: Give at least 6 months and longer (12 months or more) for those who have ongoing risks like cancer and thrombophilia. For those with idiopathic disease and residual thrombosis or high D-dimers following the first 6 months of therapy longer therapy should be used ie 12 months or more.

Cohen教授：有进行性风险如癌症和血栓倾向的患者至少服用6个月或更长时间（12个月或更长）。有特发性疾病和残存血栓或高D-二聚体患者，在最初6个月治疗后，应行更长时间治疗，如12个月或更长。

Alexander Cohen
 伦敦大学国王学院医院血管外科心血管咨询荣誉顾问，心血管I期～IV期临床试验设计、管理及分析师和流行病学工作者，国际多中心试验指导委员会成员，国际血栓与止血学会、欧洲心血管协会、英国血栓与止血学会、国际医学会澳大利亚和新西兰分会会员和Cochrane系统评价小组成员。